Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New procedure aims to zap nerves to fix slow heartbeat

NCT ID NCT07468383

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a procedure called cardioneuroablation for people with a slow heart rate (bradycardia) caused by overactive vagal nerves. Doctors use a catheter to ablate (destroy) specific nerve clusters in the heart. The trial will enroll 188 participants aged 18-65 and measure changes in average heart rate and quality of life. The goal is to see if this can reduce symptoms like dizziness and fatigue without needing a pacemaker.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
cardioneuroablation (catheter procedure to ablate cardiac nerve clusters)
What this could lead to
If successful, this procedure could offer a non-drug, non-pacemaker option to control symptoms of slow heart rate caused by overactive vagal nerve activity.
What could go wrong
This is an early-stage study with no phase designation, so results are uncertain. The procedure is invasive and carries risks like bleeding, infection, or heart rhythm issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 188 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2025

Expected to finish

Jul 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age range: 18 - 65 years old 2. Have symptoms related to bradycardia (syncope, dizziness, blackout, palpitations, fatigue, listlessness, inability to concentrate and decreased activity endurance, etc.) 3. Meet one of the following conditions: ①Dynamic electrocardiogram shows an average heart rate of less than 50 beats per minute or there is a heart arrest lasting more than 3 seconds during the day; ②Transient second or third degree atrioventricular conduction block without hemodynamic disorders during the day 4. The atropine test showed that the sinus heart rate increased by ≥ 25%, or the heart rate was ≥ 90 beats per minute, or the atrioventricular conduction block was significantly improved to be no more than first-degree atrioventricular conduction block. Exclusion Criteria: 1. A history of severe trauma caused by bradycardia 2. Regular use of antiarrhythmic drugs within the past 3 months 3. Prior implantation of a cardiac pacemaker 4. Existing implantation of, or indication for implantation of, electronic devices with pacing function, such as cardiac contractility modulators (CCMs), implantable cardioverter-defibrillators (ICDs), or cardiac resynchronization therapy (CRT) devices 5. Bradycardia or atrioventricular block caused by medications or other reversible factors (e.g., hyperkalemia, hypothyroidism) 6. Bradycardia or atrioventricular block associated with obstructive sleep apnea syndrome (OSAS) 7. Coronary revascularization within the past 3 months, or unstable coronary heart disease despite standardized medical treatment or revascularization 8. Stroke or transient ischemic attack (TIA) within the past 3 months 9. A history of open-heart surgery 10. Severe congenital heart disease 11. Complicated with severe ventricular arrhythmia 12. Severe cardiac insufficiency with left ventricular ejection fraction (LVEF) ≤ 35% 13. Severe cardiomyopathy, such as hypertrophic obstructive cardiomyopathy (HOCM), dilated cardiomyopathy (DCM), or cardiac amyloidosis 14. Severe aortic or mitral valve stenosis 15. Pregnancy or lactation period 16. Expected survival time of less than 1 year 17. Refusal to sign the informed consent form 18. Other conditions deemed ineligible by the researchers

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Autonomic nervous system diseases are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Beijing Anzhen Hospital, Capital Medical University

    RECRUITING

    Beijing, China, 100029, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.